 - Presented promising preliminary pharmacokinetic and clinical data on EPI-7386 in metastatic castration-resistant prostate cancer at 2021 AACR - Raised approximately 150 million in a public offering HOUSTON and VANCOUVER, BC, May 6, 2021 PRNewswire - ESSA Pharma Inc. ESSA or the Company NASDAQ: EPIX, a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2021. All references to in this release refer to United States dollars, unless otherwise indicated. 